ReviewUnited European gastroenterology journal2022
Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.
Review in United European gastroenterology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 5 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Systematic Review and Meta-Analysis: Plant-Based Therapy for Irritable Bowel Syndrome.Phytotherapy research : PTR · 2026Pooled it
- A Clinical Practice Update for the Management of Patients With Disorders of Gut-Brain Interaction and Altered Food Intake Behavior.Neurogastroenterology and motility · 2026Guideline
- European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN. Part 1: Definitions, Clinical Phenotypes, and Diagnostic Testing for Malabsorption.United European gastroenterology journal · 2025Guideline
- Efficacy of a Low-FODMAP Diet for Coeliac Patients with Persistent IBS-like Symptoms despite a Gluten-Free Diet: A Systematic Review.Nutrients · 2024Pooled it
- Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023.Digestion · 2024Guideline
- Trial
- Lactiplantibacillus plantarum P9 for chronic diarrhea in young adults: a large double-blind, randomized, placebo-controlled trial.Nature communications · 2024Trial
- [Efficacy of navel application of Jianpiwenyang Gel for chronic diarrhea of spleen and stomach weakness type: a randomized controlled trial and analysis of the mechanism].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Trial
- Prevalence and Lack of Cross-Sectional Association Between Positive Lactulose Breath Test Findings and Fecal Calprotectin Positivity in Patients with Functional Diarrhea.Diagnostics (Basel, Switzerland) · 2026Article
- A Previous History of Endometriosis Elevates Irritable Bowel Syndrome Risk in Middle-Aged and Older Women: A UK Biobank Cohort Study of 225,703 Participants.Digestive diseases and sciences · 2026Article
- Evaluating the correlation of intestinal ultrasound and fecal calprotectin with endoscopic severity scores in assessing disease activity in ulcerative colitis patients.Journal of ultrasound · 2026Article
- Comparative Study on Burden, Features and Determinants of Disorders of Gut-Brain Interaction Between Southern Europe and the Rest of Continent: Results From the Rome Foundation Global Epidemiology Study.United European gastroenterology journal · 2026Article
- Irritable bowel syndrome with diarrhea: time to change practice?Current opinion in gastroenterology · 2026Review
- Elevated fecal calprotectin values appear more common following esophagogastric than colon surgery.Journal of surgical case reports · 2026Article
- Nutritional Management of Irritable Bowel Syndrome.Nutrients · 2026Review
- Revisiting Abdominal Pain in IBS: From Pathophysiology to Targeted Management with Alverine Citrate/Simeticone.Journal of clinical medicine · 2026Review
- Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines.Nutrients · 2026Review
- Diarrhea management: from pathophysiology to microbiota modulation.Therapeutic advances in gastroenterology · 2026Review
- Influence of Sacral and Thoracolumbar Spinal Nerve Electrical Stimulation on Colonic Motility in Anesthetized Yucatan Male Pigs.Neurogastroenterology and motility · 2026Article
- Irritable Bowel Syndrome in Inflammatory Bowel Disease: An Evidence-Based Practical Review.Journal of clinical medicine · 2025Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
30 authors at 20 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome with diarrhoea (IBS-D) and functional diarrhoea (FDr) are the two major functional bowel disorders characterized by diarrhoea. In spite of their high prevalence, IBS-D and FDr are associated with major uncertainties, especially regarding their optimal diagnostic work-up and management. A Delphi consensus was performed with experts from 10 European countries who conducted a literature summary and voting process on 31 statements. Quality of evidence was evaluated using the grading of recommendations, assessment, development, and evaluation criteria. Consensus (defined as >80% agreement) was reached for all the statements. The panel agreed with the potential overlapping of IBS-D and FDr. In terms of diagnosis, the consensus supports a symptom-based approach also with the exclusion of alarm symptoms, recommending the evaluation of full blood count, C-reactive protein, serology for coeliac disease, and faecal calprotectin, and consideration of diagnosing bile acid diarrhoea. Colonoscopy with random biopsies in both the right and left colon is recommended in patients older than 50 years and in presence of alarm features. Regarding treatment, a strong consensus was achieved for the use of a diet low fermentable oligo-, di-, monosaccharides and polyols, gut-directed psychological therapies, rifaximin, loperamide, and eluxadoline. A weak or conditional recommendation was achieved for antispasmodics, probiotics, tryciclic antidepressants, bile acid sequestrants, 5-hydroxytryptamine-3 antagonists (i.e. alosetron, ondansetron, or ramosetron). A multinational group of European experts summarized the current state of consensus on the definition, diagnosis, and management of IBS-D and FDr.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.